N@N

Isotechnika reports second quarter 2010 financial results

_{//health-fitness.news-articles.net/content/2010/ .. ports-second-quarter-2010-financial-results.html}
^{Published in Health and Fitness on Wednesday, August 11th 2010 at 14:50 GMT by Market Wire}  

 Isotechnika Pharma Inc. Consolidated Condensed Interim Statements of Operations and Comprehensive Income (Loss) (Unaudited) ------------------------------------------------------------------------- (expressed in thousands of Canadian dollars) Three Months Ended Six Months Ended June 30 June 30 June 30 June 30 2010 2009 2010 2009 $ $ $ $ Revenue Research and development revenues 980 - 1,993 - Licensing revenue 491 102 829 281 Contract services and other 19 54 128 132 ---------------------------------------- 1,490 156 2,950 413 ---------------------------------------- Expenses Research and development, net 1,023 1,493 2,425 3,902 Corporate and administration 684 1,315 1,409 2,339 Amortization of property and equipment 206 225 423 452 Amortization and write-down of intellectual property 218 31 254 203 Contract services and other 5 35 33 56 Interest and prepayment costs on long-term debt - 225 - 1,077 Loss on disposal of equipment - (2) - (57) ---------------------------------------- 2,136 3,322 4,544 7,972 ---------------------------------------- Loss before the undernoted (646) (3,166) (1,594) (7,559) ---------------------------------------- Other income (expense) Net gain on plan of arrangement - 2,345 - 2,345 Foreign exchange gain (loss) (11) 85 - 50 Interest income 1 9 4 34 ---------------------------------------- (10) 2,439 4 2,429 ---------------------------------------- Net loss from continuing operations (656) (727) (1,590) (5,130) Net income from discontinued operations 170 255 1,900 529 ---------------------------------------- Net income (loss) for the period (486) (472) 310 (4,601) Other comprehensive income - - - - ---------------------------------------- Comprehensive income (loss) for the period (486) (472) 310 (4,601) ---------------------------------------- ----------------------------------------